Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016 vs Treatment of Physician's Choice in Advanced Triple-Negative Breast Cancer
NCT07533123Phase 3Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JSKN016 in triple-negative breast cancer (TNBC), sponsored by Alphamab Oncology. Started Mar 2026; status: recruiting.
02
Drugs
JSKN016
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07533123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533123.